DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies

Recruiting

Conditions: Follicular Lymphoma
Diffuse Large B-cell Lymphoma
Acute Lymphoblastic Leukemia

Interventions: Other: tisagenlecleucel

First Posted Date: 2022-09-15

Last Posted Date: 2024-05-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT05541341

Locations: 🇧🇷
Novartis Investigative Site, Sao Paulo, Brazil

Risk Perception in Multiple Sclerosis

Completed

Conditions: Multiple Sclerosis

Interventions: Other: Non High Efficacy Therapy (Non-HET)
Other: High Efficacy Therapy (HET)

First Posted Date: 2022-09-06

Last Posted Date: 2022-11-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 4361

Registration Number: NCT05528666

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection

Completed

Conditions: Diabetic Macular Edema

Interventions: Other: Beovu

First Posted Date: 2022-09-02

Last Posted Date: 2024-07-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 222

Registration Number: NCT05526729

Locations: 🇯🇵
Novartis Investigative Site, Osaka, Japan

A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery.

Phase 2

Active, not recruiting

Conditions: Acute Kidney Injury Following Cardiac Surgery

Interventions: Other: Placebo
Drug: TIN816

First Posted Date: 2022-09-01

Last Posted Date: 2025-04-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 98

Registration Number: NCT05524051

Locations: 🇺🇸
Mayo Clinic Phoenix, Phoenix, Arizona, United States
🇺🇸
Duke Univ Medical Center, Durham, North Carolina, United States
🇺🇸
Univ of Texas Southwest Med Center, Dallas, Texas, United States

and more 1 locations

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Phase 3

Active, not recruiting

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: LOU064 (blinded)
Drug: Placebo
Drug: LOU064 (open label)

First Posted Date: 2022-08-23

Last Posted Date: 2025-05-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 695

Registration Number: NCT05513001

Locations: 🇺🇸
Allervie Clinical Research, Birmingham, Alabama, United States
🇺🇸
Cahaba Derm and skin hlth ctr 27, Birmingham, Alabama, United States
🇺🇸
Research Solutions of Arizona, Litchfield Park, Arizona, United States

and more 42 locations

Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis

Completed

Conditions: Psoriasis

Interventions: Drug: Secukinumab

First Posted Date: 2022-08-23

Last Posted Date: 2022-11-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1518

Registration Number: NCT05513014

Locations: 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury

Phase 2

Completed

Conditions: Acute Kidney Injury Due to Sepsis

Interventions: Biological: TIN816 70 mg lyophilisate powder
Other: Placebo

First Posted Date: 2022-08-19

Last Posted Date: 2025-05-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT05507437

Locations: 🇪🇸
Novartis Investigative Site, Valencia, Spain

To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF

Phase 2

Terminated

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Placebo
Drug: LTP001
Drug: Standard of Care (SoC)

First Posted Date: 2022-08-11

Last Posted Date: 2024-10-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 46

Registration Number: NCT05497284

Locations: 🇺🇸
University of Kansas Hospital Main Centre, Kansas City, Kansas, United States
🇺🇸
University of Alabama at Birmingham ., Birmingham, Alabama, United States
🇵🇱
Novartis Investigative Site, Bialystok, Poland

Characteristics of Patients With Sickle Cell Disease

Completed

Conditions: Sickle Cell Disease

Interventions: Other: Crizanlizumab

First Posted Date: 2022-08-10

Last Posted Date: 2022-11-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 540

Registration Number: NCT05494541

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Phase 1

Withdrawn

Conditions: Hepatic Impairment

Interventions: Drug: TNO155

First Posted Date: 2022-08-05

Last Posted Date: 2024-02-29

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT05490030

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy